mb66
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02579083)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, passive
Human immunodeficiency virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mb66
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02579083 | Phase 1 | Jan 1, 2016 | Boston University, Brown University, Mapp Biopharmaceutical, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Brown University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Mapp Biopharmaceutical | For profit | 1 | 1 | 1 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1